BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37580017)

  • 21. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
    Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
    Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
    Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
    Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
    Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
    Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
    Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
    Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoexpression of SDHB, FH, and CK20 among eosinophilic renal tumors: A tissue microarray study.
    Karatay H; Ozluk Y; Dogan MA; Erdem S; Kilicaslan I
    Ann Diagn Pathol; 2021 Oct; 54():151788. PubMed ID: 34246177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Morphology in Predicting Fumarate Hydratase-deficient Uterine Leiomyomas in Young Women.
    Bayram A; Bagbudar S; Sozen H; Onder S; Yavuz E
    Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):657-660. PubMed ID: 37751278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
    Joseph NM; Solomon DA; Frizzell N; Rabban JT; Zaloudek C; Garg K
    Am J Surg Pathol; 2015 Nov; 39(11):1529-39. PubMed ID: 26457356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Case Report of Aggressive Fumarate Hydrase-deficient Renal Cell Carcinoma With Loss of HLA Antigens.
    Miura Y; Motoshima T; Anami T; Takemura K; Kinowaki K; Oka S; Urakami S; Kamba T; Komohara Y
    Cancer Diagn Progn; 2023; 3(4):522-527. PubMed ID: 37405222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
    Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female.
    Wyvekens N; Anderson WJ; Kim YX; Carter M; Hirsch MS
    Int J Surg Pathol; 2022 Apr; 30(2):184-189. PubMed ID: 34180725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
    Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
    PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.